In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Prenatal Screening describes tests that detect potential problems that affect the viability and development of the fetus using both less invasive and more invasive sampling techniques. GlobalData uses proprietary data and analytics to provide a comprehensive report on the prenatal screening devices market, including market shares of different players within Portugal. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the prenatal screening market in Portugal was Danaher followed by Illumina, Quidelortho, Eurofins Scientific, F. Hoffmann-La Roche, Siemens, Revvity, Thermo Fisher Scientific and Abbott Laboratories.
Prenatal Screening include Free Beta Human Chorionic Gonadotropin (hCG) Tests, Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, Unconjugated Estriol (uE3) Tests, Alpha-Fetoprotein (AFP) Tests, Inhibin A Tests and Non-invasive prenatal testing (NIPT).
The value of the prenatal screening devices market within Portugal was expected to be over $1m in 2023.
For the latest complete market share analysis of prenatal screening device market in Portugal, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.